- Report
- January 2025
- 17 Pages
Global
From €14321EUR$14,995USD£11,976GBP
- Report
- November 2024
- 328 Pages
Global
From €4583EUR$4,799USD£3,833GBP
- Report
- October 2024
- 199 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- September 2024
- 110 Pages
Global
From €5682EUR$5,950USD£4,752GBP
- Report
- October 2024
- 184 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- October 2024
- 188 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- October 2024
- 193 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- October 2024
- 191 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- October 2024
- 196 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- October 2024
- 180 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- December 2024
- 100 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- August 2024
- 175 Pages
Global
From €4775EUR$5,000USD£3,993GBP
- Report
- March 2025
- 149 Pages
Global
From €2864EUR$2,999USD£2,395GBP
- Report
- August 2024
- 146 Pages
Global
From €2864EUR$2,999USD£2,395GBP
- Report
- April 2024
- 138 Pages
Global
From €2864EUR$2,999USD£2,395GBP
- Report
- March 2025
- 89 Pages
Global
From €5348EUR$5,600USD£4,472GBP
- Report
- March 2025
- 92 Pages
Global
From €5348EUR$5,600USD£4,472GBP
- Report
- March 2025
- 202 Pages
Global
From €5205EUR$5,450USD£4,353GBP
- Report
- March 2025
- 258 Pages
Global
From €4727EUR$4,950USD£3,953GBP
- Report
- February 2025
- 272 Pages
Global
From €5205EUR$5,450USD£4,353GBP

Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin. The market for diabetes devices specifically catered to Type 1 diabetes includes a variety of products that assist patients in monitoring and managing their blood glucose levels. Key devices within this market are blood glucose meters, continuous glucose monitoring (CGM) systems, and insulin pumps. Blood glucose meters provide immediate readings of blood glucose levels, while CGM systems offer the advantage of real-time, dynamic glucose information, revealing trends and providing alerts for rapid changes. Insulin pumps are used for the continuous subcutaneous injection of insulin, and they can often be integrated with CGM systems to create a closed-loop system, sometimes referred to as an artificial pancreas, which adjusts insulin delivery based on CGM readings.
The Type 1 diabetes devices market is marked by technological advancements that focus on improving the quality of life for patients by making devices more user-friendly, accurate, and capable of data integration for better diabetes management. Research and development in this sector are vigorous, with an emphasis on creating devices that are less invasive, more connected (leveraging smartphone technology), and capable of providing more detailed data analytics for personalized treatment plans.
Several key players in the Type 1 diabetes devices market include Medtronic, Dexcom, Abbott Laboratories, Insulet Corporation, and Tandem Diabetes Care. These companies are at the forefront of developing and providing advanced diabetes care technologies to patients, clinicians, and healthcare providers. Show Less Read more